Inhibitors of the Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Pathway Clear Prion-Infected Cells from PrPSc
Open Access
- 14 September 2005
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 25 (37) , 8451-8456
- https://doi.org/10.1523/jneurosci.2349-05.2005
Abstract
Prions represent a unique class of infectious agents in which the normal cellular prion protein (PrPC) is converted to an abnormal isoform (PrPSc), which accumulates in the brain and constitutes the major, if not the only, component of the infectious particle. Factors that still remain to be identified may facilitate the conversion of PrPCto PrPSc. In the present study, we first demonstrated that a growth factor of the neurotrophin family, brain-derived neurotrophic factor (BDNF), stimulates the formation of PrPScin a gonadotropin-releasing hormone-secreting neuronal cell line (GT1-1 cells) infected with the Rocky Mountain Laboratory (RML) strain of scrapie as determined by Western blot analysis. We then observed that the prion-infected cells can be cleared from PrPScby treatment with three inhibitors of mitogen-activated protein kinase kinase 1/2 (MEK1/2) [1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene and 2-(2-amino-3-methyoxyphenyl)-4H-1-benzopyran-4-one, as well as α-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl) benzeneacetonitrile, which passes the blood–brain barrier], a component of one of the intracellular signaling pathways activated by BDNF. The MEK1/2 inhibitors were also efficient in clearing PrPScfrom prion-infected GT1-1 cells stimulated to accumulate high levels of PrPScby enhanced serum concentrations in the medium or by the use of a serum-free neuron-specific neurobasal medium. PrPScdid not reappear in the cultures within 5 weeks after completion of treatment. We conclude that inhibitors of the MEK1/2 pathway can efficiently and probably irreversibly clear PrPScfrom prion-infected cells. The MEK pathway may therefore be a suitable target for therapeutic intervention in prion diseases.Keywords
This publication has 40 references indexed in Scilit:
- Approaches to Therapy of Prion DiseasesAnnual Review of Medicine, 2005
- Scrapie Protein Degradation by Cysteine Proteases in CD11c + Dendritic Cells and GT1-1 Neuronal CellsJournal of Virology, 2004
- Cellular Heparan Sulfate Participates in the Metabolism of PrionsJournal of Biological Chemistry, 2003
- Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s diseaseProgress in Neurobiology, 2000
- Enhanced Expression of Cellular Prion Protein Gene by Insulin or Nerve Growth Factor in Immortalized Mouse Neuronal Precursor Cell LinesBiochemical and Biophysical Research Communications, 2000
- Reversion of prion protein conformational changes by synthetic b-sheet breaker peptidesThe Lancet, 2000
- Scrapie prion proteins accumulate in the cytoplasm of persistently infected cultured cells.The Journal of cell biology, 1990
- Further characterization of scrapie replication in PC12 cellsJournal of General Virology, 1990
- Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells.The Journal of cell biology, 1990
- Dextran Sulphate 500 Delays and Prevents Mouse Scrapie by Impairment of Agent Replication in SpleenJournal of General Virology, 1984